|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,932.60 INR | -0.90% |
|
-0.15% | +12.38% |
| 07-15 | India's Sun Pharma wins South Africa approval to launch generic Ozempic | RE |
| 07-15 | Sun Pharma Wins South Africa Approval for Generic Semaglutide | MT |
| Market Cap | 4,637B 48.15B 42.08B 38.83B 35.79B 67.46B 68.96B 464B 183B 2,271B 181B 177B 7,818B | P/E 2027 * |
35.3x | P/E 2028 * | 29.9x |
|---|---|---|---|---|---|
| Enterprise Value | 4,364B 45.31B 39.6B 36.54B 33.68B 63.48B 64.89B 437B 172B 2,137B 170B 166B 7,357B | EV / Sales 2027 * |
6.67x | EV / Sales 2028 * | 5.89x |
| Free-Float |
44.39% | Yield 2027 * |
0.82% | Yield 2028 * | 0.92% |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | -0.90% | ||
| 1 week | -0.15% | ||
| Current month | +3.76% | ||
| 1 month | +6.16% | ||
| 3 months | +15.34% | ||
| 6 months | +15.80% | ||
| Current year | +12.38% |
| 1 week | 1,910 |  | 1,962.7 |
| 1 month | 1,820.9 | | 1,962.7 |
| Current year | 1,583.7 | | 1,962.7 |
| 1 year | 1,548 | | 1,962.7 |
| 3 years | 1,063.85 | | 1,962.7 |
| 5 years | 672.55 | | 1,962.7 |
| 10 years | 312 | | 1,962.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 73 | 25/05/2018 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.90% | -0.15% | +13.46% | +79.34% | 48.15B | |
| -0.23% | -1.65% | +65.14% | +115.81% | 35.59B | |
| -0.76% | -1.44% | -4.30% | +37.38% | 11.9B | |
| -0.88% | -0.62% | +16.38% | +89.65% | 11.85B | |
| +0.19% | +2.87% | +34.92% | +127.54% | 9.31B | |
| -0.75% | -0.91% | +18.26% | +37.23% | 6.91B | |
| -9.93% | +0.35% | -29.90% | +14.89% | 6.13B | |
| +3.37% | -0.10% | +49.31% | -4.38% | 7.02B | |
| -2.25% | -2.08% | +0.40% | +218.27% | 6.55B | |
| -0.97% | +2.11% | +22.72% | +138.54% | 4.43B | |
| Average | -1.31% | +0.27% | +18.64% | +85.43% | 14.78B | |
| Weighted average by Cap. | -0.88% | -0.35% | +25.88% | +87.92% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 654B 6.79B 5.94B 5.48B 5.05B 9.52B 9.73B 65.47B 25.75B 320B 25.51B 24.95B 1,103B | 729B 7.57B 6.62B 6.11B 5.63B 10.61B 10.85B 73B 28.71B 357B 28.44B 27.82B 1,230B |
| Net income | 133B 1.38B 1.2B 1.11B 1.02B 1.93B 1.97B 13.27B 5.22B 64.94B 5.17B 5.06B 224B | 157B 1.63B 1.42B 1.31B 1.21B 2.28B 2.33B 15.67B 6.16B 76.68B 6.11B 5.97B 264B |
| Net Debt | -273B -2.84B -2.48B -2.29B -2.11B -3.97B -4.06B -27.35B -10.76B -134B -10.66B -10.42B -461B | -341B -3.55B -3.1B -2.86B -2.64B -4.97B -5.08B -34.18B -13.44B -167B -13.32B -13.02B -576B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 17/07/26 | ₹1,932.60 | -0.90% | 2,475,664 |
| 16/07/26 | ₹1,950.10 | -0.07% | 1,396,189 |
| 15/07/26 | ₹1,951.50 | +0.46% | 2,283,494 |
| 14/07/26 | ₹1,942.60 | +1.10% | 2,822,124 |
| 13/07/26 | ₹1,921.40 | -0.73% | 1,573,176 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
